Skip to content

ArriVent BioPharma

US · AVBP #3057 by market cap Listed 2024
10.52 -0.74 -6.57%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 1.71 Cheap vs history 11th percentile
5-year average 2.42 · #203 of 513 in Biotechnology
P/E ratio -3.61 Expensive vs history 99th percentile
5-year average -8.08 · forward -3.40
P/S ratio 134.58 Expensive vs history 99th percentile
5-year average 0.98 · forward 73.51 · #303 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
ArriVent BioPharma (AVBP) 544.13M -2.92 1.38 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value18.09 Economic moatNone UncertaintyVery High

Trading 72.0% below Morningstar's fair value estimate.

Fair value

ArriVent BioPharma Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 28% discount to our quantitative fair value estimate of $18.09 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's valuation metrics increase our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its price to cash ratio of 1.8, which falls in the bottom 20% globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be undervalued.

Conversely, the firm's balance sheet is potentially concerning. Low leverage can limit a company's ability to invest in growth, potentially reducing shareholder value compared with a balanced use of debt and equity financing. The firm's long term debt to assets ratio of 0.0001, for example, ranks in the bottom 20% compared with global peers. With little long-term debt relative to assets, this firm has a "lazy" balance sheet, which can depress returns on invested capital. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

ArriVent BioPharma discussion 0 comments

Add a comment